Table 4. Validation of risk factors adopted by Padua Prediction Score in the study population, with adjusted OR of VTE.
| Risk factor in Padua Prediction Score | Relative | Cases | Controls | Crude | Adjusted ORa | Adjusteda |
|---|---|---|---|---|---|---|
| Risk Score | (n = 902) | (n = 902) | P value | (95% CI) | P value | |
| Active cancerb | 3 | 164 (18.2) | 168 (18.6) | 0.808 | - | - |
| Previous VTE | 3 | 146 (16.2) | 4 (0.4) | < 0.001 | 47.89 (17.22–133.20) | < 0.001 |
| (with the exclusion of superficial vein thrombosis) | ||||||
| Reduced mobility | 3 | 373 (41.4) | 122 (13.5) | < 0.001 | 4.23 (3.29–5.43) | < 0.001 |
| Already known thrombophilic condition | 3 | 18 (2.0) | 1 (0.1) | < 0.001 | 22.44 (2.86–176.14) | 0.003 |
| Recent (≤ 1 mo) trauma and/or surgery | 2 | 56 (6.2) | 27 (3.0) | 0.001 | 1.77 (1.04–3.01) | 0.036 |
| Elderly age (≥ 70 y) | 1 | 319 (35.4) | 235 (26.1) | < 0.001 | 1.38 (1.10–1.74) | 0.006 |
| Heart and/or respiratory failure | 1 | 151 (16.7) | 83 (9.2) | < 0.001 | 1.55 (1.12–2.14) | 0.009 |
| Acute myocardial infarction or ischemic stroke | 1 | 53 (5.9) | 9 (1.0) | < 0.001 | 5.20 (2.40–11.27) | < 0.001 |
| Acute infection and/or rheumatologic disorder | 1 | 406 (45.0) | 261 (28.9) | < 0.001 | 2.06 (1.65–2.58) | < 0.001 |
| Obesity (BMI ≥ 30)c | 1 | 32 (3.5) | 18 (2.0) | 0.045 | 2.18 (1.16–4.12) | 0.016 |
| Ongoing hormonal treatment | 1 | 10 (1.1) | 19 (2.1) | 0.133 | - | - |
| VTE prophylaxis | - | 37 (4.1) | 55 (6.1) | 0.054 | 0.42 (0.25–0.71) | 0.001 |
OR = odds ratio, VTE = venous thromboembolism, CI = confidence interval, BMI = body mass index, mo = month
a
Variables that had a P-value < 0.05 in univariable crude analysis were selected for inclusion in the final multivariable model and VTE prophylaxis was also included.
b
Cancer patients with local or distant metastases and/or in whom chemotherapy or radiotherapy had been performed in the previous 6 months
c
Available in 583 cases, 449 controls.